ImmunityBio Inc (IBRX) concluded trading on Wednesday at a closing price of $3.90, with 18.52 million shares of worth about $72.24 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.74% during that period and on February 19, 2025 the price saw a gain of about 16.42%. Currently the company’s common shares owned by public are about 696.83M shares, out of which, 76.10M shares are available for trading.
Stock saw a price change of 23.03% in past 5 days and over the past one month there was a price change of 32.65%. Year-to-date (YTD), IBRX shares are showing a performance of 52.34% which decreased to -18.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $10.53 during that period. The average intraday trading volume for ImmunityBio Inc shares is 5.84 million. The stock is currently trading 18.11% above its 20-day simple moving average (SMA20), while that difference is up 24.88% for SMA50 and it goes to -17.07% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 696.83M outstanding shares and institutions hold larger chunk of about 11.58% of that.
The stock has a current market capitalization of $2.85B and its 3Y-monthly beta is at 0.70. It has posted earnings per share of -$0.89 in the same period. It has Quick Ratio of 2.64. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 13.34% while standing at 9.91% over the month.
Stock’s fiscal year EPS is expected to rise by 30.43% while it is estimated to increase by 16.25% in next year. EPS is likely to grow at an annualized rate of 32.58% for next 5-years, compared to annual growth of 1.17% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Piper Sandler stated ImmunityBio Inc (IBRX) stock as a Neutral in their note to investors on May 12, 2023, suggesting a price target of $4 for the stock.
